UNSPSC 51293002: Amitriptyline

This classification denotes a tricyclic antidepressant with the molecular formula C20H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1806D8D52K, chemically known as 10,11-dihydro-n,n-dimethyl-5h-dibenzo(a,d)heptalene-delta(sup 5),gamma-propylamine but generally known as amitriptyline, which bears US NIH Compound Identifier 2160. Amitriptyline most often comes in base, chloride, hydrochloride, n-glucuronide, and n-oxide forms.

UNSPSC 51293002 Amitriptyline is a Commodity code that nominally designates a single pharmaceutical product, yet recent state and local procurement activity under this code shows minimal direct alignment with amitriptyline specifically. Instead, opportunities tagged to the code reflect broader pharmaceutical procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products. State and local purchasing under pharmaceutical commodity codes spans county health departments, state HHS commissions, and cooperative purchasing alliances serving multi-jurisdictional networks of government facilities. The solicitations reveal a trend toward aggregated procurement of pharmaceutical inventories to support public health initiatives, emergency response, and employee health benefit programs rather than procurement of single active pharmaceutical ingredients.

Geographic activity centers on Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering a Request for Proposal issued January 20, 2026, with a March 26, 2026, response deadline for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon. Seminole County, Florida posted an Invitation for Bid (IFB 60459723LAS) on June 30, 2026, with a July 26, 2026, deadline for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries; the contract includes a two-year term with an optional one-year renewal and carries potential FEMA funding with associated federal compliance requirements. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct state pharmacy benefit relationships outside traditional pharmacy benefit manager and group purchasing organization channels. The mismatch between the code's nominal scope and actual buying activity suggests this Commodity code may be misapplied to pharmaceutical procurement more broadly rather than specifically targeting amitriptyline.